Clinical Study
The Role of Disease Activity Score 28 in the Evaluation of Articular Involvement in Systemic Lupus Erythematosus
Table 1
Main demographic, clinical, laboratory, and therapeutic features of the SLE patients (
) enrolled in the present study.
| | Disease history | At the time of enrolment |
| Clinical manifestations (%) | | | Skin involvement | 59.4 | 20.3 | Oral ulcers | 26.1 | 2.8 | Serositis | 24.6 | 4.3 | Hematologic disorder | 40.6 | 27.5 | Kidney involvement | 26.1 | 4.3 | Neurologic involvement | 5.8 | 0 | Laboratory evaluation (%) | | | Anti-nuclear antibodies | 100 | 94.2 | Anti-double stranded DNA | 73.5 | 34.8 | Anti-Sm | 35 | 24.6 | Anti-SSA | 49.2 | 49.3 | Anti-SSB | 20.2 | 7.2 | Anticardiolipin IgG and/or IgM | 46.4 | 17.4 | Anti-β2-glycoprotein I IgG and/or IgM | 27.5 | 7.2 | Lupus anticoagulant | 27.5 | 7.2 | Low C3 and/or C4 serum levels | 65.2 | 52.2 | Drugs (%) | | | Hydroxychloroquine | 97.1 | 76.8 | Methotrexate | 34.8 | 8.7 | Azathioprine | 34.8 | 11.6 | Mycophenolate mofetil | 28.9 | 17.4 | Cyclosporin A | 33.3 | 10.1 | Salazopyrine | 1.4 | 0 | Rituximab | 5.9 | 0 | Cyclophosphamide | 10.1 | 0 | Steroid dosage (mg/week, median, range) | — | 35 (0–175) |
|
|